Understanding how SOCS1 affects uveal melanoma treatment with immunotherapy
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS EL PASO · NIH-10897221
This study is looking at how a protein called SOCS1 affects how well uveal melanoma patients respond to immunotherapy, with the hope of finding better ways to treat this tough cancer by understanding why current treatments aren't working as well as they should.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS EL PASO (nih funded) |
| Locations | 1 site (EL PASO, UNITED STATES) |
| Trial ID | NIH-10897221 on ClinicalTrials.gov |
What this research studies
This research investigates the role of SOCS1, a protein that regulates immune responses, in how uveal melanoma (UM) patients respond to immunotherapy. The study aims to identify the mechanisms behind the poor effectiveness of current treatments for UM, which has not benefited from existing therapies like immune checkpoint inhibitors. By analyzing tumor samples from patients, the researchers hope to uncover important biomarkers that could predict treatment responses and improve therapeutic strategies for UM. The ultimate goal is to enhance the effectiveness of immunotherapy for patients suffering from this challenging form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uveal melanoma, particularly those who have not responded well to existing treatments.
Not a fit: Patients with other types of melanoma or those who have not been diagnosed with uveal melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for uveal melanoma patients, potentially increasing survival rates and treatment effectiveness.
How similar studies have performed: While there has been significant research on immunotherapy in other melanoma types, the specific role of SOCS1 in uveal melanoma is less explored, making this a novel investigation.
Where this research is happening
EL PASO, UNITED STATES
- UNIVERSITY OF TEXAS EL PASO — EL PASO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: QIN, YONG — UNIVERSITY OF TEXAS EL PASO
- Study coordinator: QIN, YONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancer Center, Cancers